Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 2019;321(3):288–300.
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365(9472):1687–1717.
   PubMed Web of Science ®Google Scholar
• , Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomized trials. Lancet. 2012;379(9814):432–444.
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and Meta-analysis of randomised controlled trials. BMC Cancer. 2010;10(1):337.
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27(8):1177–1183.
   PubMed Web of Science ®Google Scholar
• Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381–5387.
   PubMed Web of Science ®Google Scholar
• Do T, Medhekar R, Bhat R, et al. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2015;153(3):591–597.
   PubMed Web of Science ®Google Scholar
• Takabatake D, Taira N, Hara F, et al. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol. 2009;39(8):478–483.
   PubMed Web of Science ®Google Scholar
• Renner P, Milazzo S, Liu JP, et al. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev. 2012;10:CD007913.
   PubMed Web of Science ®Google Scholar
• Clark OAC, Lyman G, Castro AA, et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev. 2003;4(3):CD003039.
   Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Database of abstracts of reviews of effects (DARE): quality-assessed. Reviews J Clin Oncol. 2007;25(21):3158–3167.
   Google Scholar
• Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–2484.
   PubMed Web of Science ®Google Scholar
• Crawford J, Becker PS, Armitage JO, et al. Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(12):1520–1541.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Armitage JO. Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11(6):511–513.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. JI. 2015;195(4):1341–1349.
   Google Scholar
• Li X, Zheng H, Yu MC, et al. Is pegylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and Meta-analysis. Support Care Cancer. 2020;28(11):5085–5097.
   PubMed Web of Science ®Google Scholar
• Bond TC, Szabo E, Gabriel S, et al. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract. 2018;24(6):412–423.
   PubMed Web of Science ®Google Scholar
• Lee KH, Kim JY, Lee MH, et al. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Support Care Cancer. 2016;24(4):1709–1717.
   PubMed Web of Science ®Google Scholar
• Kang KW, Lee BH, Jeon MJ, et al. Efficacy and safety of two pegfilgrastim biosimilars: tripegfilgrastim and pegteograstim. Cancer Med. 2020;9(17):6102–6110.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, McCune JS, Blough DK, et al. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care. 2010;16(9):678–686.
   PubMed Web of Science ®Google Scholar
• Potosky AL, Malin JL, Kim B, et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst. 2011;103(12):979–982.
   PubMed Web of Science ®Google Scholar
• Waters GE, Corrigan P, Gatesman M, et al. Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract. 2013;9(4):203–206.
   PubMedGoogle Scholar
• Health Insurance Review and Assessment. Service (HIRA). Details on the application standards and methods of prescription drug coveragy for cancer patients. 2019. Available from: https://www.hira.or.kr/ebooksc/ebook_554/ebook_554_201911041106139820.pdf.
   Google Scholar
• Lee J, Lee JE, Kim Z, et al. Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy. Ann Surg Treat Res. 2018;94(5):223–228.
   PubMed Web of Science ®Google Scholar
• Jeon YW, Lim ST, Gwak H, et al. Clinical impact of primary prophylactic pegfilgrastim in breast cancer patients receiving adjuvant docetaxel-doxorubicin-cyclophosphamide chemotherapy. J Breast Cancer. 2020;23(5):521–532.
   PubMed Web of Science ®Google Scholar
• Marventano S, Grosso G, Mistretta A, et al. Evaluation of four comorbidity indices and Charlson comorbidity index adjustment for colorectal cancer patients. Int J Colorectal Dis. 2014;29(9):1159–1169.
   PubMed Web of Science ®Google Scholar
• Kim L, Kim JA, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health. 2014;36:e2014008.
   PubMedGoogle Scholar
• KOICD. Korean Standard Classification of Diseases (KCD)-7 code. Korean Standard Statistical Classification. 2016. Available from: https://www.koicd.kr/kcd/kcd.do
   Google Scholar
• Health Insurance Review and Assessment. Service (HIRA). health insurance medical care expenses and hira drug ingredient codes. 2018. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000
   Google Scholar
• Song SO, Jung CH, Song YD, et al. Background and data configuration process of a nationwide population-based study using the Korean national health insurance system. Diabetes Metab J. 2014;38(5):395–403.
   PubMedGoogle Scholar
• Gawade PL, Li S, Henry D, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer. 2020;28(9):4413–4424.
   PubMed Web of Science ®Google Scholar
• Weycker D, Doroff R, Hanau A, et al. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice: a retrospective observational study. BMC Cancer. 2019;19(1):792.
   PubMed Web of Science ®Google Scholar
• Link H, Kerkmann M, Holtmann L, et al. Working groups supportive care (ASORS now AGSMO) and medical oncology (AIO) within the german cancer society (DKG). G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer. 2019;27(4):1459–1469.
   PubMed Web of Science ®Google Scholar
• Yu JL, Chan K, Kurin M, et al. Clinical outcomes and cost-effectiveness of primary prophylaxis of febrile neutropenia during adjuvant docetaxel and cyclophosphamide chemotherapy for breast cancer. Breast J. 2015;21(6):658–664.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
   PubMed Web of Science ®Google Scholar
• Fontanella C, Bolzonello S, Lederer B, et al. Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. Breast Care (Basel). 2014;9(4):239–245.
   PubMed Web of Science ®Google Scholar
• Balducci L, Hardy CL, Lyman GH. Hemopoiesis and aging. Cancer Treat Res. 2005;124:109–134.
   Google Scholar
• Rajan SS, Stearns SC, Lyman GH, et al. Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat. 2011;130(1):255–266.
   PubMed Web of Science ®Google Scholar
• Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12(12):1416–1424.
   PubMed Web of Science ®Google Scholar
• Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205.
   PubMedGoogle Scholar
• Du XL, Lairson DR, Begley CE, et al. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. JCO. 2005;23(34):8620–8628.
   PubMed Web of Science ®Google Scholar
• Falandry C, Campone M, Cartron G, et al. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer: Oxford. 2010;46(13):2389–2398.
   PubMed Web of Science ®Google Scholar
• Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000;18(8):1764–1770.
   PubMed Web of Science ®Google Scholar
• Hawkins A, Murphy A, McNamara M, et al. A survey of oncologists' perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Educ. 2020;35(1):178–186.
   PubMed Web of Science ®Google Scholar